We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
+$224M
Cap. Flow %
9.21%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Miscellaneous 82.86%
2 Healthcare 14.52%
3 Energy 1.33%
4 Technology 0.46%
5 Materials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGEN icon
301
PUT
Precigen
PGEN
$2.51B
$426K 0.02%
135
+44
+48% +$2.15K
MACK
302
CALL
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$426K 0.02%
+64
New +$5.22K
QURE icon
303
PUT
uniQure
QURE
$2.99B
$425K 0.02%
+208
New +$5.48K
NVRO
304
DELISTED
NEVRO CORP.
NVRO
$421K 0.02%
+9,066
New +$439K
CARM
305
DELISTED
Carisma Therapeutics
CARM
$413K 0.02%
+8,577
New +$529K
IMUX icon
306
PUT
Immunic
IMUX
$141M
$404K 0.02%
+3
New +$15K
RMTI icon
307
PUT
Rockwell Medical
RMTI
$31.6M
$381K 0.02%
4
– –
AERI
308
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$381K 0.02%
+215
New +$3.89K
CYTR
309
DELISTED
CytRx Corp
CYTR
$378K 0.02%
+26,597
New +$451K
ACGN
310
PUT
DELISTED
Aceragen Inc
ACGN
$372K 0.02%
+1
New +$3.54K
RMTI icon
311
Rockwell Medical
RMTI
$31.6M
$358K 0.01%
422
+261
+162% +$378K
AFMD
312
DELISTED
Affimed
AFMD
$350K 0.01%
+5,677
New +$703K
GMED icon
313
Globus Medical
GMED
$10B
$345K 0.01%
+16,700
New +$423K
PRQR icon
314
ProQR Therapeutics
PRQR
$260M
$320K 0.01%
21,950
-61,050
-74% -$1.02M
ZLTQ
315
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$320K 0.01%
+10,000
New +$331K
PTCT icon
316
PUT
PTC Therapeutics
PTCT
$5.48B
$318K 0.01%
119
– –
OXGN
317
DELISTED
OXIGENE INC COM
OXGN
$305K 0.01%
328,431
+69,996
+27% +$91.2K
TLPH icon
318
Talphera
TLPH
$61.8M
$301K 0.01%
4,930
-2,205
-31% -$181K
NSPH
319
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$297K 0.01%
181,946
+12,915
+8% +$33.4K
BHC icon
320
PUT
Bausch Health
BHC
$2.12B
$285K 0.01%
16
-69
-81% -$16.1K
LXRX icon
321
PUT
Lexicon Pharmaceuticals
LXRX
$894M
$279K 0.01%
+260
New +$2.84K
HSTO
322
DELISTED
Histogen Inc. Common Stock
HSTO
$278K 0.01%
313
-1,554
-83% -$1.42M
PVLA
323
Palvella Therapeutics
PVLA
$2.18B
$276K 0.01%
+1,884
New +$420K
SIOX
324
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$272K 0.01%
+2,632
New +$309K
RPTP
325
PUT
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$264K 0.01%
436
-594
-58% -$7.28K
11 12
13
14 15

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management deployed $224M of net new capital in Q3 2015, opening 130 new positions and adding to 120 existing holdings. Its largest new stake was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 89% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Lipocine, an estimated $7.13M trimmed.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.